Abstract:The current global COVID-19 pandemic is caused by beta coronavirus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which already infected over 10 million and caused 500 thousand deaths by June 2020. Overproduction of cytokines triggered by COVID-19 infection, known as "cytokine storm", is a highly risk factor associated with disease severity. However, how COVID-19 infection induce cytokine storm is still largely unknown. Accumulating in vitro and in vivo evidence suggests that gut is also susceptible to COVID19 infection: Human intestinal organoids, an in vitro model which mimic the specific cell type and spatial structure of the intestine, were susceptible to SARS-CoV2 infection; A significant fraction of patients reported gut symptoms; Viral RNA may persist for more than 30 days and infectious virus could be isolated in fecal samples. The gastrointestinal tract is the primary site of interaction between the host immune system with symbiotic and pathogenic microorganisms. The bacteria resident in our gastrointestinal tract, known as gut microbiota, is important to maintain the homeostasis of our immune system. While imbalance of gut microbiota, or dysbiosis, is associated with multiple inflammation diseases5. It's possible that SARS-CoV-2 infection may lead to alternation of gut microbiota thus worsen the host symptom. IL-18 is a proinflammatory cytokine produced multiple enteric cells, including intestinal epithelial cells (IECs), immune cells as well as enteric nervous system, and was shown to increase in the serum of COVID-19 patients. Immunoglobin A (IgA) is mainly produced in the mucosal surfaces, in humans 40-60mg kg-1 day-1 than all other immunoglobulin isotypes combined, and at least 80% of all plasma cells are located in the intestinal lamina propria. Recent study showed that SARS-CoV-2 specific IgA in the serum is positively correlate with the disease severity in COVID-19 patients11. Here we investigated the alterations of microbiota in COVID-19 patients, and its correlation with inflammatory factor IL-18 and SARS-CoV2 specific IgA. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by a grant from the National Key R&D Program of China (2018YFA0508000) (SZ), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29030101) (SZ), the National Natural Science Foundation of China (81822021, 91842105, 31770990, 81821001) (SZ), and the Fundamental Research Funds for the Central Universities (WK2070000159) (SZ). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This is an observational cohort study. This study is part of the project of "Construction of a bio-information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui" (ChiCTR2000030331). This study was approved by the institutional board of the First Affiliated Hospital of University of Science and Technology of China (2020-XG(H)-009). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data are available upon request.

Characterization of the Intestinal Microbiome in Healthy Adults over Sars-Cov-2 Vaccination

BBIBP-CorV Vaccination against the SARS-CoV-2 Virus Affects the Gut Microbiome.

Alterations of Fecal Metabolome Associated with BBIBP-CorV Vaccines Against the SARS-CoV-2 Virus.

Stability of gut microbiome after COVID-19 vaccination in healthy and immuno-compromised individuals

Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events

Exploring the associations between gut microbiota composition and SARS-CoV-2 inactivated vaccine response in mice with type 2 diabetes mellitus

Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine

Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity

The Faecal Metabolome in COVID-19 Patients is Altered and Associated with Clinical Features and Gut Microbes

The gut microbiota modifies antibody durability and booster responses after SARS-CoV-2 vaccination

Alterations in the oral microbiome of individuals with a healthy oral environment following COVID-19 vaccination

Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV

P2 COVID-19 Vaccination Response in Immunosuppressed Patients with IBD is Associated with Altered Gut Microbiota Function

Effects of SARS-CoV-2 Vaccine (vero Cells) on Disease Activity in Patients with Inflammatory Bowel Disease in China: a Multicenter Study

Mo1095 ATRIAL NATRIURETIC PEPTIDE ATTENUATES INTESTINAL INFLAMMATION IN DSS-INDUCED COLITIS MICE

The Gut Microbiota and Metabolome Are Associated with Diminished COVID-19 Vaccine-Induced Antibody Responses in Immunosuppressed Inflammatory Bowel Disease Patients.

Analysis of the intestinal microbiota in COVID 19 patients and its correlation with the inflammatory factor IL 18 and SARS CoV 2 specific IgA

A comprehensive perspective on the interaction between gut microbiota and COVID-19 vaccines

Effects of BBIBP-CorV vaccine on gut microbiota and short-chain fatty acids in mice exposed to bis (2-ethylhexyl) phthalate and dioctyl terephthalate

SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition

A pro-inflammatory gut mucosal cytokine response is associated with mild COVID-19 disease and superior induction of serum antibodies